Piper sees negative BRACA decisions as isolated for Myriad Genetics Piper Jaffray says its work suggests "little negative provider updates" for Myriad Genetics (MYGN) beyond Horizon BCBS recently naming LabCorp (LH) as its in-patient BRCA test provider and Health Plus's update urging the discontinuation of Myriad for BRCA testing. The firm believes recent negative BRACAnalysis decisions are isolated and keeps an Overweight rating on Myriad with a $44 price target.
Myriad RBM joins Institut Pasteur in TB collaboration Myriad RBM, a wholly owned subsidiary of Myriad Genetics, announced that it will assist the Institut Pasteur in a public-private research collaboration to fight the global tuberculosis, or TB, epidemic. This research project is funded by the Bill & Melinda Gates Foundation through a grant to the Institut Pasteur. The proof-of-concept study will evaluate patients with latent and active TB infections who are affiliated with the South African Tuberculosis Vaccine Initiative clinical study sites. The goals of this study are to field-test Myriad RBM's TruCulture system as a point-of-care blood collection and immune response monitoring method and to stratify patients with active and latent tuberculosis.